| pubmed-article:15292062 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15292062 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15292062 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:15292062 | lifeskim:mentions | umls-concept:C0079613 | lld:lifeskim |
| pubmed-article:15292062 | lifeskim:mentions | umls-concept:C0039736 | lld:lifeskim |
| pubmed-article:15292062 | lifeskim:mentions | umls-concept:C1504389 | lld:lifeskim |
| pubmed-article:15292062 | lifeskim:mentions | umls-concept:C1512034 | lld:lifeskim |
| pubmed-article:15292062 | lifeskim:mentions | umls-concept:C1515895 | lld:lifeskim |
| pubmed-article:15292062 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:15292062 | pubmed:dateCreated | 2004-11-4 | lld:pubmed |
| pubmed-article:15292062 | pubmed:abstractText | To improve the antimyeloma effect of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation in multiple myeloma, we investigated in a phase 1/2 study the effect of low-dose thalidomide (100 mg) followed by DLI in 18 patients with progressive disease or residual disease and prior ineffective DLI after allografting. The overall response rate was 67%, including 22% complete remission. Major toxicity of thalidomide was weakness grade I/II (68%) and peripheral neuropathy grade I/II (28%). Only 2 patients experienced mild grade I acute graft versus host disease (aGvHD) of the skin, while no grades II to IV aGvHD was seen. De novo limited chronic GvHD (cGvHD) was seen in 2 patients (11%). The 2-year estimated overall and progression-free survival were 100% and 84%, respectively. Adoptive immunotherapy with low-dose thalidomide and DLI induces a strong antimyeloma effect with low incidence of graft versus host disease. | lld:pubmed |
| pubmed-article:15292062 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15292062 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15292062 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:15292062 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15292062 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15292062 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15292062 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:15292062 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:15292062 | pubmed:author | pubmed-author:NaglerArnonA | lld:pubmed |
| pubmed-article:15292062 | pubmed:author | pubmed-author:ShimoniAvicha... | lld:pubmed |
| pubmed-article:15292062 | pubmed:author | pubmed-author:KrögerNicolau... | lld:pubmed |
| pubmed-article:15292062 | pubmed:author | pubmed-author:ZabelinaTatja... | lld:pubmed |
| pubmed-article:15292062 | pubmed:author | pubmed-author:ZanderAxel... | lld:pubmed |
| pubmed-article:15292062 | pubmed:author | pubmed-author:FehseBorisB | lld:pubmed |
| pubmed-article:15292062 | pubmed:author | pubmed-author:AyukFrancisF | lld:pubmed |
| pubmed-article:15292062 | pubmed:author | pubmed-author:RengesHelmutH | lld:pubmed |
| pubmed-article:15292062 | pubmed:author | pubmed-author:ZagrivnajaMar... | lld:pubmed |
| pubmed-article:15292062 | pubmed:author | pubmed-author:LioznovMichae... | lld:pubmed |
| pubmed-article:15292062 | pubmed:author | pubmed-author:SchiederHeike... | lld:pubmed |
| pubmed-article:15292062 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15292062 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:15292062 | pubmed:volume | 104 | lld:pubmed |
| pubmed-article:15292062 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15292062 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15292062 | pubmed:pagination | 3361-3 | lld:pubmed |
| pubmed-article:15292062 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15292062 | pubmed:meshHeading | pubmed-meshheading:15292062... | lld:pubmed |
| pubmed-article:15292062 | pubmed:meshHeading | pubmed-meshheading:15292062... | lld:pubmed |
| pubmed-article:15292062 | pubmed:meshHeading | pubmed-meshheading:15292062... | lld:pubmed |
| pubmed-article:15292062 | pubmed:meshHeading | pubmed-meshheading:15292062... | lld:pubmed |
| pubmed-article:15292062 | pubmed:meshHeading | pubmed-meshheading:15292062... | lld:pubmed |
| pubmed-article:15292062 | pubmed:meshHeading | pubmed-meshheading:15292062... | lld:pubmed |
| pubmed-article:15292062 | pubmed:meshHeading | pubmed-meshheading:15292062... | lld:pubmed |
| pubmed-article:15292062 | pubmed:meshHeading | pubmed-meshheading:15292062... | lld:pubmed |
| pubmed-article:15292062 | pubmed:meshHeading | pubmed-meshheading:15292062... | lld:pubmed |
| pubmed-article:15292062 | pubmed:meshHeading | pubmed-meshheading:15292062... | lld:pubmed |
| pubmed-article:15292062 | pubmed:meshHeading | pubmed-meshheading:15292062... | lld:pubmed |
| pubmed-article:15292062 | pubmed:meshHeading | pubmed-meshheading:15292062... | lld:pubmed |
| pubmed-article:15292062 | pubmed:meshHeading | pubmed-meshheading:15292062... | lld:pubmed |
| pubmed-article:15292062 | pubmed:meshHeading | pubmed-meshheading:15292062... | lld:pubmed |
| pubmed-article:15292062 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15292062 | pubmed:articleTitle | Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. | lld:pubmed |
| pubmed-article:15292062 | pubmed:affiliation | Department of Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany. nkroeger@uke.uni-hamburg.de. | lld:pubmed |
| pubmed-article:15292062 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15292062 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15292062 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15292062 | lld:pubmed |
